1 recruiting, 1 unknown. 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Aplagon Oy: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia APAC - dose level 0.50 mg/kg,, Unfractionated heparin (UFH), APAC dose level 1: 0.25 mg/kg, - Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia | Phase 2 | Recruiting | Aplagon Oy | 42 | 2026-01-29 | 2026-04-09 |
| Safety, Tolerability, and Biodistribution of [89Zr]Zr-DFO-APAC in Subjects With PAOD/CLI and Healthy Volunteers (Acronyms: 89Zr = Zirconium-89, DFO = Desferrioxamine, APAC = AntiPlatelet AntiCoagulant, PET/CT = Positron Emission Tomography/Computed Tomography) [89Zr]Zr-DFO-APAC, PET/CT scan - Peripheral Arterial Occlusive Disease, Critical Limb Ischemia | Early Phase 1 | Unknown | Aplagon Oy | 10 | 2024-02-01 | 2025-01-30 |
Chronic Limb-Threatening Ischemia (2) · Peripheral Arterial Occlusive Disease 1 (2)
Heparin (1) · Sodium Chloride (1)
Finland (1) · Netherlands (1)
Jarna Hannukainen (1) · Schelto Kruijff, MD, Prof (1)
2023 (1), 2025 (1)